|
1）Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95
|
|
|
|
2）Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012; 129（3 Suppl）: S9-23
|
|
|
|
|
|
3）日本アレルギー学会 喘息ガイドライン専門部会. 喘息予防・管理ガイドライン2015. 東京: 協和企画；2015. p.142-4
|
|
|
|
|
|
4）Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers （exhaled nitric oxide or sputum eosinophils）. Thorax. 2012; 67: 199-208
|
|
|
|
|
|
5）Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015; 308: L130-40
|
|
|
|
|
|
6）Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002; 360: 1715-21
|
|
|
|
|
|
7）Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006; 27: 483-94
|
|
|
|
|
|
8）Chlumsky J, Striz I, Terl M, et al. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res. 2006; 34: 129-39
|
|
|
|
|
|
9）Giannini D, Di Franco A, Cianchetti S, et al. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. Clin Exp Allergy. 2000; 30: 1777-84
|
|
|
|
|
|
10）Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005; 115: 720-7
|
|
|
|
|
|
11）Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992; 47: 25-9
|
|
|
|
|
|
12）Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels （FENO） for clinical applications. Am J Respir Crit Care Med. 2011; 184: 602-15
|
|
|
|
|
|
13）Matsunaga K, Hirano T, Kawayama T, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int. 2010; 59: 363-7
|
|
|
|
|
14）Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest. 2008; 133: 1232-42
|
|
|
|
|
|
15）Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005; 352: 2163-73
|
|
|
|
|
|
16）Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med. 2007; 176: 231-7
|
|
|
|
|
|
17）Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012; 308: 987-97
|
|
|
|
|
|
18）Malerba M, Ragnoli B, Radaeli A, et al. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest. 2008; 134: 733-9
|
|
|
|
|
|
19）Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE（NO） and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015; 70: 115-20
|
|
|
|
|
|
20）Zhang XY, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014; 44: 1137-45
|
|
|
|
|
|
21）Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132: 72-80
|
|
|
|
|
|
22）McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012; 185: 612-9
|
|
|
|
|
|
23）Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178: 218-24
|
|
|
|
|
|
24）Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma （DREAM）: a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380: 651-9
|
|
|
|
|
|
25）Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. 2014; 11: 1011-7
|
|
|
|
|
|
26）Just J, Saint-Pierre P, Gouvis-Echraghi R, et al. Childhood allergic asthma is not a single phenotype. J Pediatr. 2014; 164: 815-20
|
|
|
|
|
|
27）O’Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy. 2009; 39: 1677-83
|
|
|
|
|
|
28）Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989; 320: 271-7
|
|
|
|
|
|
29）Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011; 20: 156-74
|
|
|
|
|
|
30）Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013; 187: 804-11
|
|
|
|
|
|
31）de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013; 50: 296-301
|
|
|
|
|
|
32）Takeshita S, Kikuno R, Tezuka K, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993; 294（Pt1）: 271-8
|
|
|
|
|
|
33）Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009; 180: 388-95
|
|
|
|
|
|
34）Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012; 130: 647-54 e10
|
|
|
|
|
|
35）Matsusaka M, Kabata H, Fukunaga K, et al. Phenotype of asthma related with high serum periostin levels. Allergol Int. 2015; 64: 175-80
|
|
|
|
|
|
36）Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013; 132: 305-12 e3
|
|
|
|
|
|
37）Song JS, You JS, Jeong SI, et al. Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma. Allergy. 2015; 70: 674-81
|
|
|
|
|
|
38）Bobolea I, Barranco P, Del Pozo V, et al. Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015; 70: 540-6
|
|
|
|
|
|
39）Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365: 1088-98
|
|
|
|
|